HealthInvest Partners’s Royalty Pharma RPRX Stock Holding History

HealthInvest Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$31.3K	Buy	+791	New	+$33K	0.06%	26

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HealthInvest Partners's RPRX Position: Q4 2022 in Review

HealthInvest Partners opened a new position in Royalty Pharma (RPRX) in Q4 2022: 791 shares worth $31.3K. The stake represents 0.06% of the portfolio and ranks #26 among its holdings.

336 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

HealthInvest Partners held 791 shares of Royalty Pharma worth $31.3K as of Q4 2022.
Royalty Pharma was a new HealthInvest Partners position in Q4 2022.
Royalty Pharma made up 0.06% of HealthInvest Partners's portfolio in Q4 2022, its #26 holding.
336 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.